These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 2077520

  • 1. MPTP-induced hypoactivity in mice: reversal by L-dopa.
    Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T.
    Pharmacol Toxicol; 1990 Oct; 67(4):295-301. PubMed ID: 2077520
    [Abstract] [Full Text] [Related]

  • 2. Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa.
    Fredriksson A, Palomo T, Archer T.
    Behav Pharmacol; 2000 Nov; 11(7-8):571-81. PubMed ID: 11198128
    [Abstract] [Full Text] [Related]

  • 3. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
    Fredriksson A, Palomo T, Archer T.
    J Neural Transm (Vienna); 1999 Nov; 106(9-10):889-909. PubMed ID: 10599871
    [Abstract] [Full Text] [Related]

  • 4. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
    Fredriksson A, Archer T.
    Behav Brain Res; 2003 Feb 17; 139(1-2):31-46. PubMed ID: 12642174
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.
    Fredriksson A, Gentsch C, Archer T.
    J Neural Transm Gen Sect; 1994 Feb 17; 97(3):197-209. PubMed ID: 7873129
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.
    Fredriksson A, Archer T.
    J Neural Transm Gen Sect; 1995 Feb 17; 102(1):19-34. PubMed ID: 8785021
    [Abstract] [Full Text] [Related]

  • 7. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
    Fredriksson A, Danysz W, Quack G, Archer T.
    J Neural Transm (Vienna); 2001 Feb 17; 108(2):167-87. PubMed ID: 11314771
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.
    Fornai F, Battaglia G, Gesi M, Giorgi FS, Orzi F, Nicoletti F, Ruggieri S.
    Brain Res; 2000 Dec 22; 887(1):110-7. PubMed ID: 11134595
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.
    Neurobiol Dis; 2012 Mar 22; 45(3):1051-67. PubMed ID: 22198503
    [Abstract] [Full Text] [Related]

  • 15. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
    Treseder SA, Jackson M, Jenner P.
    Br J Pharmacol; 2000 Apr 22; 129(7):1355-64. PubMed ID: 10742291
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.